在南非，改用贝达喹啉治疗利福平耐药结核病：一项回顾性队列分析。
Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.
机构信息
Division of Infectious Diseases, Brown University Alpert School of Medicine, Providence, RI, United States of America.
Department of Science and Technology, National Research Foundation Centre of Excellence in Biomedical Tuberculosis Research, South Africa Medical Research Council for Tuberculosis Research, Cape Town, South Africa.
出版信息
PLoS One. 2019 Oct 17;14(10):e0223308. doi: 10.1371/journal.pone.0223308. eCollection 2019.
South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.
南非率先制定了苯并恶嗪（BDQ）作为单一药物替代来管理利福平耐药结核病方案毒性的指南。我们在回顾性队列中检查了使用 BDQ 的原因：超过 75%的患者因毒性（耳毒性或肾功能障碍）而不是耐药性而改用 BDQ。
Zotero 插件